Initial Therapeutics
Preventing pathogenic protein synthesis
Preventing pathogenic protein synthesis
Initial Therapeutics is a biotechnology startup founded in 2020 with a mission to prevent pathogenic protein synthesis. The company is focused on discovering and developing a new class of small-molecule medicines specifically designed to halt pathogenic protein formation in the earliest stages. This approach is unique as it differs starkly from protein degradation and other interventions that only recognize and tackle proteins after they have been fully formed. Initial Therapeutics is headquartered in the United States and has recently secured a significant $75.00M Series A investment on 01 May 2023 with Apple Tree Partners as the lead investor.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $75.00M | 1 |
|
01 May 2023 |
| Seed Round | $3.80M | 1 |
|
16 Jul 2020 |
No recent news or press coverage available for Initial Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
